Wide Ranks

ALNY

Alnylam Pharmaceuticals, Inc.

253.74

Top Statistics
Market Cap 32 B Forward PE 488.22 Revenue Growth -33.30 %
Current Ratio 2.75 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -15.86 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -247.25 Enterprise / Revenue 15.60 Price To Sales Trailing12 Months 15.62
Profitability
Profit Margins -15.86 % Operating Margins -15.35 %
Balance Sheet
Total Cash 2 B Total Cash Per Share 21.55 Total Debt 2 B
Total Debt To Equity 8426.14 Current Ratio 2.75 Book Value Per Share 0.2510
All Measures
Short Ratio 394.00 % Message Board Id finmb_2796659 Fax 617 551 8101
Shares Short Prior Month 4 M City Cambridge Uuid b8c27535-96f9-31bb-99f8-fad7a2cefe4b
Previous Close 253.35 First Trade Date Epoch Utc 1 B Book Value 0.2510
Beta 0.3860 Total Debt 2 B Volume 702711
Price To Book 1010.92 Fifty Two Week Low 141.98 Total Cash Per Share 21.55
Total Revenue 2 B Shares Short Previous Month Date 1 B Target Median Price 300.00
Max Age 86400 Recommendation Mean 2.03 Sand P52 Week Change 0.3133
Operating Margins -15.35 % Target Mean Price 298.77 Net Income To Common -332264000
Short Percent Of Float 0.0333 Implied Shares Outstanding 128 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 999100 Average Volume10days 999100
Total Cash 2 B Next Fiscal Year End 1 B Revenue Per Share 16.52
Held Percent Insiders 0.0042 Ebitda Margins -6.31 % Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 253.35
Target Low Price 178.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 271.93
Open 253.98 Free Cashflow 309 M State MA
Dividend Yield 0.00 % Return On Assets -0.0292 Time Zone Short Name EST
Trailing Eps -2.61 Day Low 250.27 Address1 675 West Kendall Street
Shares Outstanding 128 M Price Hint 2 Target High Price 400.00
Website https://www.alnylam.com 52 Week Change 0.5081 Average Volume 866392
Forward Eps -1.22 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 256.80 % Is_sp_500 False Regular Market Day High 256.02
Profit Margins -15.86 % Debt To Equity 8426.14 Fifty Two Week High 304.39
Day High 256.02 Shares Short 3 M Regular Market Open 253.98
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue 15.60
Revenue Growth -33.30 % Shares Percent Shares Out 0.0290 Operating Cashflow 56 M
Currency USD Time Zone Full Name America/New_York Market Cap 32 B
Is_nasdaq_100 False Zip 02142 Quote Type EQUITY
Industry Biotechnology Long Name Alnylam Pharmaceuticals, Inc. Regular Market Day Low 250.27
Held Percent Institutions 0.9810 Current Price 253.74 Address2 Henri A. Termeer Square
Enterprise To Ebitda -247.25 Financial Currency USD Current Ratio 2.75
Gross Margins 85.37 % Industry Disp Biotechnology Number Of Analyst Opinions 30
Country United States Float Shares 128 M Two Hundred Day Average 213.55
Enterprise Value 32 B Price To Sales Trailing12 Months 15.62 Forward PE 488.22
Regular Market Volume 702711 Ebitda -132146000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.

Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH.

Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial.

Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran.

It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.